SOURCE: OctoPlus N.V.

March 08, 2010 09:31 ET

OctoPlus publishes prospectus for listing of shares issued on 18 December 2009

LEIDEN, NETHERLANDS--(Marketwire - March 8, 2010) -


OctoPlus N.V. ("OctoPlus", or the "Company") (Euronext: OCTO) publishes today a prospectus for the admission to listing and trading on Euronext Amsterdam by NYSE Euronext ("Euronext Amsterdam") of 211,806 newly issued ordinary shares as per 9 March 2010. The relevant shares were issued in the context of the private placement that OctoPlus successfully completed on 18 December 2009. Through a private placement of 3,232,106 new ordinary shares OctoPlus raised EUR 4.0 million from new and existing investors. 3,020,300 of the newly issued shares were admitted to listing and trading on Euronext Amsterdam on 21 December 2009. For the remaining 211,806 shares a listing prospectus is published today. This prospectus was approved by the Netherlands Authority for the Financial Markets (AFM) on 5 March 2010. The prospectus is available in the Investor Relations section on the Company's website: www.octoplus.nl.

Financial calendar 2010

OctoPlus also announces that it will publish its annual results for the year 2009 on Thursday 18 March, which will be discussed in a conference call and webcast at 10:00 AM that day. The Annual General Meeting of Shareholders is scheduled for Wednesday 12 May at 14:00 PM in Leiden.

For further information, please contact: Rianne Roukema, Corporate Communications: telephone number +31 (71) 524 1071, or send an e-mail to Investor Relations at IR@octoplus.nl.

About OctoPlus

ctoPlus is a drug delivery service company committed to the creation of improved pharmaceutical products that are based on OctoPlus' proprietary drug delivery technologies and have fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. OctoPlus focuses on the development of long-acting, controlled release versions of known protein therapeutics, other drugs, and vaccines on behalf of its clients.

The clinically most advanced product incorporating our technology is Biolex Therapeutics' lead product Locteron(®), a controlled release formulation of interferon alpha for the treatment of chronic hepatitis C. OctoPlus licensed Locteron exclusively to Biolex in October 2008. Locteron is being manufactured for Biolex by OctoPlus and is currently in Phase IIb clinical studies.

In addition, OctoPlus is a leading European provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industries, with a focus on difficult-to-formulate active pharmaceutical ingredients.

OctoPlus is listed on Euronext Amsterdam by NYSE Euronext under the symbol OCTO. For more information about OctoPlus, please visit our website www.octoplus.nl.

This document may contain certain forward-looking statements relating to the business, financial performance and results of OctoPlus and the industry in which it operates. These statements are based on OctoPlus' current plans, estimates and projections, as well as its expectations of external conditions and events. In particular the words "expect", "anticipate", "predict", "estimate", "project", "plan", "may", "should", "would", "will", "intend", "believe" and similar expressions are intended to identify forward-looking statements. We caution investors that a number of important factors, and the inherent risks and uncertainties that such statements involve, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements. In the event of any inconsistency between an English version and a Dutch version of this document, the English version will prevail over the Dutch version.

Click here for the press release in PDF format: http://hugin.info/137076/R/1391755/349507.pdf

Contact Information